Pilot Program Aimed At Advancing Medical Device Development Set To Launch
Cardiology devices to have first opportunity to enroll
Executive Summary
The US Food and Drug Administration’s Total Product Lifecycle Advisory Program pilot, which was authorized under MDUFA V, will begin rolling out next year. The program is designed to speed up the development of innovative medical devices and make them more readily available to patients.
You may also be interested in...
US Interim Funding Bill Gets President Biden’s Signature; Window Narrows For IVD Reg Reform
Passed by the US House and signed into law on 30 September, the Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023, avoids a partial government shutdown and furloughs in FDA user-fee programs including MDUFA. Policy riders stripped from the legislation, including for FDA oversight of lab-developed tests, could still find their way into a final FY 2023 spending omnibus.
MDUFA V: Industry, FDA Tangle Over TAP Program, Agency Finances, Reinstatement Of Fifth-Year Offset Funds
In newly published meeting minutes, industry and the US FDA continued to clash over a proposal to create a new pre-submission advisory program and what to do with carryover user-fee funds.
‘STeP’ By ‘STeP’: FDA Finalizes Accelerated Pathway For Novel Devices, Combo Products
The US FDA released a final guidance document on 5 January that sets in place its new voluntary Safer Technologies Program, or STeP. Modeled after the agency’s burgeoning Breakthrough Devices Program, STeP is for innovative devices and device-led combo products heading for a PMA, 510(k) or de novo regulatory route that aim to treat less serious conditions than devices accepted into the Breakthrough program.